CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity is intended for gynecologic oncologists, medical oncologists, gynecologists and other healthcare providers involved in the treatment of gynecologic cancers.
  
  OVERVIEW OF ACTIVITY
  As a group, gynecologic sarcomas are relatively rare, and given their wide heterogeneity, specific histologic subtypes present even less frequently in clinical practice. As such, gynecologic and medical oncologists may lack experience caring for patients with any given uterine sarcoma, including the most common, uterine leiomyosarcoma (uLMS). Even so, and despite the fact that conventional treatment options for sarcomas of the female genital tract had remained unchanged for several years, recently published research has led to several newly approved therapies poised to disrupt established standards. With the proliferation of these research advances, it is important for any healthcare professional involved in the care of these individuals to remain up to date in order to appropriately offer patients with uLMS or other gynecologic sarcomas high-quality treatment.
  
  This CME program developed from the proceedings of a satellite symposium held during the Society of Gynecologic Oncology’s 2019 Annual Meeting on Women’s Cancer features video slide presentations given by leading researchers with an expertise in gynecologic cancers on the published data that drive clinical decision-making. By providing information on the emerging research developments and their potential application to routine practice, this activity is designed to assist medical oncologists, gynecologic oncologists and other healthcare providers with the formulation of up-to-date clinical management strategies.
  
  LEARNING OBJECTIVES
  

  • Appreciate the importance of multidisciplinary collaboration in the diagnosis and management of gynecologic sarcomas, and use this knowledge to design a process to optimize tissue procurement, accurate histological assessment, tertiary care referral and treatment outcome.
  • Develop an evidence-based strategy for the treatment of Stage I to III uterine sarcoma, considering the potential contributions of surgery, radiation therapy and cytotoxic therapy.
  • Use guideline-endorsed monitoring protocols and techniques to effectively screen patients with localized uterine leiomyosarcoma for metastases.
  • Appraise available safety and efficacy data with targeted and cytotoxic therapies approved for the treatment of advanced gynecologic sarcomas, and consider how these agents can be optimally incorporated into clinical management algorithms.
  • Recall new data with investigational agents demonstrating promising activity in patients with uterine sarcomas, and discuss ongoing trial opportunities with eligible individuals.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  HOW TO USE THIS CME ACTIVITY
  This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:
  
  Amanda Nickles Fader, MD
  Associate Professor and Director
  The Kelly Gynecologic Oncology Service
  Director, Center for Rare Gynecologic Cancers
  Johns Hopkins School of Medicine
  Baltimore, Maryland
  
  Advisory Committee: Clovis Oncology, Merck.
  
  Mario M Leitao Jr, MD
  Attending Surgeon and Member, Division of Gynecology
  Professor, Weill Cornell Medical College
  Director, Gynecologic Oncology Fellowship Program
  Director, Minimal Access and Robotic Surgery Program
  Department of Surgery
  Memorial Sloan Kettering Cancer Center
  New York, New York
  
  No relevant conflicts of interest to disclose.
  
  Angeles Alvarez Secord, MD, MHSc
  Professor, Duke Cancer Institute
  Duke University Health System
  Durham, North Carolina
  
  Advisory Committee: AstraZeneca Pharmaceuticals LP, Clovis Oncology, Genentech, Janssen Biotech Inc, Merck, Roche Laboratories Inc; Contracted Research: AbbVie Inc, Amgen Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Clovis Oncology, Eisai Inc, Exelixis Inc, Genentech, Immutep Ltd, Incyte Corporation, Merck, Roche Laboratories Inc, Seattle Genetics, Tesaro.
  
  Brian A Van Tine, MD, PhD
  Medical Oncology
  Associate Professor of Medicine
  Sarcoma Program Director
  Washington University in St Louis
  Siteman Cancer Center
  St Louis, Missouri
  
  Advisory Committee and Consulting Agreements: Adaptimmune, CytRx Corporation, Daiichi Sankyo Inc, Epizyme Inc, Immune Design, Janssen Biotech Inc, Lilly, Pfizer Inc; Contracted Research: Merck, Pfizer Inc, TRACON Pharmaceuticals Inc; Speakers Bureau: Adaptimmune, Caris Life Sciences, Janssen Biotech Inc, Lilly; Other Remunerated Activities: Merck, Pfizer Inc, TRACON Pharmaceuticals Inc.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech, Genmab, Genomic Health Inc, Gilead Sciences Inc, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, Teva Oncology, Tokai Pharmaceuticals Inc and Tolero Pharmaceuticals.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.
  
  This activity is supported by an educational grant from Lilly.
  
  Hardware/Software Requirements:
  A high-speed Internet connection
  A monitor set to 1280 x 1024 pixels or more
  Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
  Adobe Flash Player 27 plug-in or later
  Adobe Acrobat Reader
  (Optional) Sound card and speakers for audio
  
  Release date: June 2019
  Expiration date: June 2020